Loading...
|
Please use this identifier to cite or link to this item:
https://nccur.lib.nccu.edu.tw/handle/140.119/60625
|
Title: | 台灣生技企業特殊籌資工具之探索性研究 The preliminary study of special financing tool for Taiwan Biotech coporations |
Authors: | 鄭師安 |
Contributors: | 顏錫銘 鄭師安 |
Keywords: | 生技企業 風險調整淨現值 籌資工具 附賣回權股票 Biotechnology Coporations rNPV Financing Tool Puttable Stock |
Date: | 2010 |
Issue Date: | 2013-09-09 11:24:20 (UTC+8) |
Abstract: | 根據美國生技產業協會(Biotechnology Industry Organization, BIO)的資料顯示,純研發型的生技公司難以取得投資資金,且投資者對公司的現金部位益發看重。而我國的台灣經濟研究院調查也指出國內生技廠商在研發階段所面臨到的重大困難是「資金取得不易」,這些正反應出國內外投資者對生技產業特殊性的疑慮,進而不願意投入大量資金。 為解決國內生技研發型公司資金不足之問題,本論文分析了美國生技公司籌資狀況及常使用之工具,並考量台灣生技產業所面臨之整體環境,為國內生技企業建立了具實用價值的特殊籌資工具及發行模式,以滿足不同的籌資需求及降低投資者的風險。而為驗證此一籌資工具之可行性,本論文也挑選國內一家生技研發型公司,以其業務及財務現況,進行特殊籌資工具之定價,並提供發行前後應注意之相關事項。 According to the research report from BIO(Biotechnology Industry Organization), it is hard for research-based biotech companies to get financing and investors are more concerned about whether the company has enough cash or not .The same result can be found in the investigation of Taiwan Institute of Economic Research(TIER).They find out the research-based biotech companies in Taiwan encounter one difficult problem - hard to get enough money to support their R&D .All these facts just reflect the special characteristics of biotech industry and the investment trend among biotech field. The goal of this thesis is to resolve the financing problem faced by the research-based biotech companies in Taiwan, so we analyze how American biotech companies get enough financing to support their R&D, and then, construct the special financing tool for the research-based biotech companies under the economical situation in Taiwan, in order to fulfill the needs of biotech companies and reduce the investment risk. In this thesis, we use a case study to verify the pricing model of special financing tool and propose some material facts should be resolved when stocks issuing. |
Reference: | 一、中文部分 1. 李京翰,「特別股發行前的融資活動對特別股的影響」,國立交通大學財務金融研究所碩士論文,2010年。 2. 林衛理,「生物科技股價評估與案例分析」,會計研究月刊,第197期,2002年。 3. 陳威光,新金融商品個案集I,智勝文化,2003年。 4. 陳威光,選擇權:理論、實務與風險管理,智勝文化,2010年。 5. 陳慧玲,「生物科技公司之投資與評價~以P生技公司為例」,國立政治大學經營管理碩士論文,2004年。 6. 財團法人生物技術開發中心,醫藥產業年鑑2003,2003年。 7. 黃文賓,「新藥價值之評估~以風險調整淨現值法評估懷特新藥公司」,國立中山大學財務管理研究所碩士論文,2002年。 8. 張芩瑜,「特別股制度問題之探討~法律與會計之交錯」,國立台北大學法律學研究所碩士論文,2008年。 9. 楊國隆,生物科技產業技術鑑價之研究,國立中山大學企業管理學系碩士在職專班碩士論文,2003年。 10. 經濟部工業局,2010生技產業白皮書,2010年。
二、外文部份 1. Bruce A. Mann, “Creative Techniques for Financing Biotechnology,” American Law Institute – American Bar Association Continuing Legal Education, November 1993. 2. Chen, A. H. and J. W. Kensinger, “Puttable Stock: A New Innovation in Equity Financing,” Financial Management, Spring 1988. 3. Fisher Black, “The Pricing of Commodity Contracts,” Journal of Financial Economics. 4. Fisher Black and Myron Scholes, “The Price of Option and Corporate Liabilities,” Journal of Political Economy, 1973. 5. Jeffrey J. Stewart, Peter N Allison and Ronald S. Johnson, “Putting a Price on Biotechnology,” Nature Biotechnology, 2001. 6. Leora Schiff and Fiona Murray, “Biotechnology Financing Dilemmas and the Role of Special Purpose Entities,” Nature Biotechnology, 2004. 7. Mark Kessel and Frederick Frank, “A Better Prescription for Drug-development Financing,” Nature Biotechnology, 2007. 8. Michael E.Solt, “SWORD Financing of Innovation in the Biotechnology Industry,” Financial Management, Summer 1993. 9. Steven A. Ross, Randolph W. Westerfield, Jeffrey Jaffe and Bradford D. Jordan, Modern Financial Management 8thed, McGraw-Hill/Irwin, 2009. |
Description: | 碩士 國立政治大學 商管專業學院碩士學位學程(AMBA) 98380001 99 |
Source URI: | http://thesis.lib.nccu.edu.tw/record/#G0098380001 |
Data Type: | thesis |
Appears in Collections: | [管理碩士學程/商管專業學院碩士學位學程 AMBA] 學位論文
|
Files in This Item:
File |
Size | Format | |
000101.pdf | 939Kb | Adobe PDF2 | 794 | View/Open |
|
All items in 政大典藏 are protected by copyright, with all rights reserved.
|